China Approves a Treatment for COVID-19 Complications
China's National Health Commission published treatment guidelines Wednesday that could make a decade-old rheumatoid arthritis drug a treatment option for patients with severe SARS-CoV-2 infections.
Actemra from Roche (OTC: RHHBY) is used to dial down out-of-control immune system responses. It's been approved in the U.S. to treat patients with severe rheumatoid arthritis -- an autoimmune disease -- since 2010. It's also been approved to treat life-threatening bouts of cytokine release syndrome (CRS) brought on by super-potent new cancer therapies.
Image source: Getty Images.
Source Fool.com
